Latest Insider Transactions at Petros Pharmaceuticals, Inc. (PTPI)
This section provides a real-time view of insider transactions for Petros Pharmaceuticals, Inc. (PTPI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Petros Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Petros Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 21
2023
|
Fady Boctor Officer |
BUY
Grant, award, or other acquisition
|
Direct |
49,645
+50.0%
|
-
|
|
Apr 26
2023
|
Bruce Bernstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,050
+42.03%
|
-
|
|
Apr 26
2023
|
Greg Bradley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,050
+42.12%
|
-
|
|
Apr 26
2023
|
Joshua Silverman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,722
+37.43%
|
-
|
|
Apr 26
2023
|
Wayne Remell Walker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,050
+42.12%
|
-
|
|
Jan 20
2023
|
Bruce Bernstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,264
+49.65%
|
-
|
|
Jan 20
2023
|
Greg Bradley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,264
+50.0%
|
-
|
|
Jan 20
2023
|
Joshua Silverman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,515
+35.78%
|
-
|
|
Jan 20
2023
|
Wayne Remell Walker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,264
+50.0%
|
-
|
|
Dec 22
2021
|
John D Shulman Director |
BUY
Open market or private purchase
|
Indirect |
145,773
+2.49%
|
$437,319
$3.43 P/Share
|
|
Nov 29
2021
|
John D Shulman Director |
BUY
Open market or private purchase
|
Indirect |
500,000
+8.25%
|
$1,500,000
$3.0 P/Share
|
|
Oct 18
2021
|
John D Shulman Director |
BUY
Open market or private purchase
|
Indirect |
1,661,807
+24.73%
|
$1,661,807
$1.72 P/Share
|
|
Dec 01
2020
|
John D Shulman Director |
BUY
Grant, award, or other acquisition
|
Indirect |
3,382,416
+50.0%
|
-
|
|
Dec 01
2020
|
Keith Lavan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
975
+50.0%
|
-
|
|
Dec 01
2020
|
Andrew Gesek President, Timm Medical |
BUY
Grant, award, or other acquisition
|
Indirect |
97
+50.0%
|
-
|
|
Dec 01
2020
|
Joshua Silverman Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|